logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

More Good News for Neurocrine Biosciences

Neurocrine Biosciences’ Product INGREZZA Improved Chorea Associated with Huntington's Disease Through Week 50  Yesterday, November 2, 2023, Neurocrine Biosciences ( NBIX ) announced interim results from the KINECT®-HD2 study about INGREZZA® (valbenazine) capsules used for long-term treatment of adults with...

Read More

November 3, 2023

0

Current News From Three Selected Biotech Firms

Three Biotech Firm in the NEWS Verona Pharma Verona Pharma plc ( VRNA ) announced that senior management will present a company overview at the following conferences in November 2023: Jefferies London Healthcare Conference Date: Wednesday, November 15, 2023 Time:...

Read More

November 8, 2023

0

About the FDA Approval of Eli Lilly's Product Zepbound for Obesity   

FDA Approval of Eli Lilly Product Zepbound for Obesity On Wednesday, Nov. 8, 2023,  the U.S. FDA approved Eli Lilly ( LLY ) product ZepboundTM ( tirzepatide ) injection for the treatment of obesity.  Zepbound is the first and only...

Read More

November 10, 2023

0

Treating Obesity: Altimmune Announces Positive Topline Results from the MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide

Altimmune Positive Topline Results Altimmune ( ALT ) announced positive results from the MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide.  Altimmune is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver fibrosis. The Company’s lead product...

Read More

December 2, 2023

0

The U.S. FDA Approved Novartis Product Fabhalta® for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

Novartis Approval Novartis ( NVS ) product Fabhalta ( iptacopan ) is a Factor B inhibitor that acts in the proximate alternative complement pathway of the immune system, It provides comprehensive control of red blood cell ( RBC ) destruction...

Read More

December 6, 2023

0

Finally, Gene Editing Therapy Has Been Approved! So Why the Stock Selloff?

Crispr Therapeutics and Vertex Pharmaceuticals Gene Editing Therapey Will Be Marketed On Nov. 16, 2023, Crispr Therapeutics ( CRSP ) and Vertex Pharmaceuticals ( VRTX ) announced that for the first time CRISPR/Cas9 Gene-Edited Therapy will be marketed. On that...

Read More

December 11, 2023

0

Anavex Life Sciences Product Blarcamesine for Alzheimer’s Disease Receives Promising News from the EMA

Anavex Life Sciences Promising News From Anavex Life Sciences  ( AVXL ) we learned that The Committee for Medicinal Products for Human Use ( CHMP ) within the European Medicines agency ( EMA ) agreed that oral blarcamesine for Alzheimer’s disease is...

Read More

December 20, 2023

0

Why Arcturus Therapeutics Holdings' Pipeline Products are Promising

The information is the first of a few biotech Companies that we believe are promising in treating severe devastating  untreatable sicknesses.  Arcturus Therapeutics Holdings Based in San Diego, California, Arcturus Therapeutics Holdings ( ARCT ) was founded in 2013. The Company...

Read More

December 27, 2023

0

Sarepta Therapeutics Submits Efficacy Supplement to Expand the ELEVIDYS Label

Sarepta Therapeutics in the NEWS On 12, 22, 2023, Sarepta Therapeutics ( SRPT ) - a precision genetic medicine for rare diseases, announced submission of an efficacy supplement to the Biologics License Application ( BLA ) for ELEVIDYS (delandistrogene moxeparvovec-rokl)...

Read More

December 28, 2023

0

Cytokinetics Announces Positive Results from a Pivotal Phase 3 Clinical Trial of Aficamten

Cytokinetics We recently became enthusiastic about Cytokinetics’ ( CYTK ) current clinical trial results. A few days ago, Cytokinetics announced positive results from SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM), the pivotal Phase 3...

Read More

December 29, 2023

0

  • Previous
  • 1
  • 2
  • ...
  • 71
  • 72
  • 73
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy